Difluprednate 0.05% versus Prednisolone acetate 1% eye drops following phacoemulsification surgery - Trial PACTR202207762785564

Timeline & Enrollment

Summary

Objective: to evaluate the efficacy and safety of difluprednate 0.05% versus prednisolone acetate 1% in patients undergoing phacoemulsification aiming at improving the outcomes in cataract surgery patients and minimizing treatment side effects.Patients and Methods: This randomized comparative controlled clinical trial which will involve patients with senile cataract. All patients will be prone to cataract extraction via phacoemulsification. Postoperatively, patients will be divided into two groups; study group: patients who will take Difluprednate 0.05% eye drops following phacoemulsification and control group: patients who will take prednisolone acetate 1% eye drops following phacoemulsification. All groups will be observed and assessed for two drops effect in managing postoperative inflammation and intraocular pressure. Additionally, tolerability to each drug will be recorded.Statistical analysis: All data will be expressed as means ± standard deviations. Serial changes in outcome measures will be compared using repeated measures analysis of variance. A P value of less than 0.05 is considered statistically significant.Expected outcomes: Difluprednate 0.05% eye drops are better than prednisolone acetate 1% regarding efficacy, safety and tolerability.

ICD-10 Classifications